AI Terminal
POLAR CAPITAL GLOBAL HEALTH.TST PLC
Fund Information / Factsheet • Dec 2, 2025
5198_rns_2025-12-02_26d77db8-9552-46f6-b965-b6f82e15d888.html
Fund Information / Factsheet
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 9508J
Polar Capital Global Health Tst PLC
02 December 2025
2nd December 2025
Polar Capital Global Healthcare Trust plc (the "Company")
Top Ten Equity Holdings and Sector and Geographic Exposure as at 28th November 2025
Polar Capital Global Healthcare Trust plc is pleased to announce that as at 28th November 2025 the top ten equity holdings and the sector and geographic breakdown were as follows:
| Top 10 Holdings | % |
| Eli Lilly & Co | 9.6% |
| AstraZeneca | 5.2% |
| Thermo Fisher Scientific | 4.4% |
| Teva Pharmaceutical Industries | 4.2% |
| CVS Health Corp | 3.8% |
| UCB | 3.3% |
| Boston Scientific Corp | 3.3% |
| H Lundbeck A/S | 3.2% |
| Cytokinetics | 2.9% |
| Ascendis Pharma A/S | 2.6% |
| Total | 42.5% |
| Sector Exposure | % |
| Pharmaceuticals | 36.1% |
| Biotechnology | 22.3% |
| Healthcare Equipment | 13.5% |
| Life Sciences Tools & Services | 9.0% |
| Healthcare Services | 8.9% |
| Healthcare Facilities | 4.2% |
| Managed Healthcare | 2.3% |
| Healthcare Distributors | 1.3% |
| Healthcare Technology | 0.9% |
| Healthcare Supplies | 0.0% |
| Cash | 1.6% |
| Total | 100.0% |
| Geographic Exposure | % |
| United States | 53.2% |
| Denmark | 12.0% |
| United Kingdom | 5.2% |
| Switzerland | 5.0% |
| Israel | 4.2% |
| Germany | 4.2% |
| India | 3.7% |
| Belgium | 3.3% |
| Japan | 3.3% |
| Netherlands | 1.6% |
| Sweden | 1.4% |
| Ireland | 1.3% |
| Cash | 1.6% |
| Total | 100.0% |
The monthly factsheet will usually be available on the Company's website on the 10th working day after the month end and includes a commentary by the investment manager. www.Polarcapitalhealthcaretrust.com
Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
PFUUPGRAPUPAGQP